tiprankstipranks
Advertisement
Advertisement
AtaiBeckley price target raised to $16 from $11 at Guggenheim
PremiumThe FlyAtaiBeckley price target raised to $16 from $11 at Guggenheim
20d ago
Buy Rating on Atai Beckley N.V. Driven by Differentiated Psychedelic TRD Program and Favorable Risk‑Reward Profile
Premium
Ratings
Buy Rating on Atai Beckley N.V. Driven by Differentiated Psychedelic TRD Program and Favorable Risk‑Reward Profile
21d ago
Trump to sign order on psychedelic used for PTSD, CBS News says
Premium
The Fly
Trump to sign order on psychedelic used for PTSD, CBS News says
21d ago
AtaiBeckley initiated with a Buy at Deutsche Bank
PremiumThe FlyAtaiBeckley initiated with a Buy at Deutsche Bank
1M ago
Psychedelic: Compass Pathways, NRx Pharma report earnings results
Premium
The Fly
Psychedelic: Compass Pathways, NRx Pharma report earnings results
1M ago
ATAI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ATAI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
Psychedelic: Clearmind advances recruitment for CMND-100 trial’s third cohort
PremiumThe FlyPsychedelic: Clearmind advances recruitment for CMND-100 trial’s third cohort
2M ago
Atai Beckley advancing BPL-003 nasal spray towards Phase 3 after FDA meeting
Premium
The Fly
Atai Beckley advancing BPL-003 nasal spray towards Phase 3 after FDA meeting
2M ago
ATAI Life Sciences: Reiterating Buy on BPL-003’s Differentiated TRD Profile, Pricing Power, and Long-Dated IP Protection
Premium
Ratings
ATAI Life Sciences: Reiterating Buy on BPL-003’s Differentiated TRD Profile, Pricing Power, and Long-Dated IP Protection
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100